GR1001550B - Αλατα βασικών πεπτιδίων με πολυεστέρες που έχουν ακραία ομάδα καρβοξύ. - Google Patents

Αλατα βασικών πεπτιδίων με πολυεστέρες που έχουν ακραία ομάδα καρβοξύ.

Info

Publication number
GR1001550B
GR1001550B GR930100213A GR930100213A GR1001550B GR 1001550 B GR1001550 B GR 1001550B GR 930100213 A GR930100213 A GR 930100213A GR 930100213 A GR930100213 A GR 930100213A GR 1001550 B GR1001550 B GR 1001550B
Authority
GR
Greece
Prior art keywords
salts
carboxy
peptides
release
terminated polyesters
Prior art date
Application number
GR930100213A
Other languages
English (en)
Inventor
Francis Gowland Hutchinson
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of GR1001550B publication Critical patent/GR1001550B/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2989—Microcapsule with solid core [includes liposome]

Abstract

Αυτή η εφεύρεση αναφέρεται σε νέα άλατα, που συνίσταται από ένα κατιόν, που παράγεται από ένα πεπτίδιο που περιέχει τουλάχιστον μία βασική ομάδα και ένα ανιόν που παράγεται από ένα πολυεστέρα καρβόξυ - τελειομένο, μέθοδος δια την βιομηχανική κατασκευή αυτών των αλάτων, και την χρήση τέτοιων αλάτων εις την κατασκευή φαρμακευτικών συνθέσεων εκτεταμένης ελευθέρωσης. Τα άλατα της εφεύρεσης έχουν μία ποικιλία ιδιοτήτων, που είναι χρήσιμες εις την τυποποίηση φαρμακευτικών συνθέσεων εκτεταμένης ελευθέρωσης, είτε τα άλατα είναι υπό καθαρή μορφή είτε ειναι εν μείγματι είτε με μία περίσσεια του πεπτιδίου υπό την ελευθέρωση και αδέσμευτη μορφή αυτού, είτε με μία περίσσεια του ελευθέρου πολυεστέρα.ω
GR930100213A 1992-05-28 1993-05-26 Αλατα βασικών πεπτιδίων με πολυεστέρες που έχουν ακραία ομάδα καρβοξύ. GR1001550B (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB@@@@A GB9211268D0 (en) 1992-05-28 1992-05-28 Salts of basic peptides with carboxyterminated polyesters

Publications (1)

Publication Number Publication Date
GR1001550B true GR1001550B (el) 1994-04-29

Family

ID=10716132

Family Applications (1)

Application Number Title Priority Date Filing Date
GR930100213A GR1001550B (el) 1992-05-28 1993-05-26 Αλατα βασικών πεπτιδίων με πολυεστέρες που έχουν ακραία ομάδα καρβοξύ.

Country Status (33)

Country Link
US (3) US5889110A (el)
JP (1) JPH08501064A (el)
KR (1) KR100293882B1 (el)
AT (1) AT407702B (el)
AU (1) AU682310B2 (el)
BE (1) BE1006143A3 (el)
CA (1) CA2136751C (el)
CH (2) CH690491A5 (el)
CZ (1) CZ292449B6 (el)
DE (2) DE4392401T1 (el)
DK (1) DK176134B1 (el)
ES (1) ES2107357B1 (el)
FI (1) FI112603B (el)
FR (1) FR2691631B1 (el)
GB (3) GB9211268D0 (el)
GR (1) GR1001550B (el)
HK (1) HK133097A (el)
HU (1) HUT70177A (el)
IE (1) IE74715B1 (el)
IL (1) IL105710A (el)
IT (1) IT1271139B (el)
LU (1) LU88559A1 (el)
MC (1) MC2330A1 (el)
NL (1) NL195056C (el)
NO (1) NO311006B1 (el)
NZ (1) NZ252268A (el)
RU (1) RU2152225C1 (el)
SE (1) SE501970C2 (el)
SG (1) SG44645A1 (el)
SK (1) SK280320B6 (el)
TW (1) TW223018B (el)
WO (1) WO1993024150A1 (el)
ZA (1) ZA933358B (el)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5665428A (en) * 1995-10-25 1997-09-09 Macromed, Inc. Preparation of peptide containing biodegradable microspheres by melt process
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
AU739469B2 (en) * 1996-12-20 2001-10-11 Alza Corporation Gel composition and methods
US20020182258A1 (en) * 1997-01-22 2002-12-05 Zycos Inc., A Delaware Corporation Microparticles for delivery of nucleic acid
US6127341A (en) * 1997-06-20 2000-10-03 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6117949A (en) * 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US20030166525A1 (en) * 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
US20070009605A1 (en) * 1998-07-23 2007-01-11 Ignatious Francis X Encapsulation of water soluble peptides
EP1240896A3 (en) * 1998-07-23 2003-03-26 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Encapsulation of water soluble peptides
US7662409B2 (en) 1998-09-25 2010-02-16 Gel-Del Technologies, Inc. Protein matrix materials, devices and methods of making and using thereof
CO5160256A1 (es) * 1999-02-08 2002-05-30 Zentaris Ag Sales de peptidos farmaceuticamente activos para la liberacion sostenida y proceso de produccion
US7018645B1 (en) 2000-04-27 2006-03-28 Macromed, Inc. Mixtures of various triblock polyester polyethylene glycol copolymers having improved gel properties
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
AU2001268159B2 (en) * 2000-06-02 2005-09-15 Eisai Inc. Delivery systems for bioactive agents
ES2382636T3 (es) * 2000-10-31 2012-06-12 Surmodics Pharmaceuticals, Inc. Método para producir composiciones para la administración mejorada de moléculas bioactivas
WO2003000156A1 (en) * 2001-06-22 2003-01-03 Southern Biosystems, Inc. Zero-order prolonged release coaxial implants
US6873915B2 (en) * 2001-08-24 2005-03-29 Surromed, Inc. Peak selection in multidimensional data
US20030095928A1 (en) * 2001-09-19 2003-05-22 Elan Pharma International Limited Nanoparticulate insulin
BRPI0213425B8 (pt) * 2001-10-19 2021-05-25 Idexx Lab Inc composições injetáveis para a liberação controlada de composto farmacologicamente ativo, usos do referido composto e método para suas preparações
MXPA04004663A (es) * 2001-11-14 2004-09-10 Alza Corp Composiciones de deposito inyectables y uso de los mismos.
US20070196415A1 (en) * 2002-11-14 2007-08-23 Guohua Chen Depot compositions with multiple drug release rate controls and uses thereof
MXPA04004665A (es) * 2001-11-14 2004-09-10 Alza Corp Composiciones de deposito inyectable y uso de los mismos.
DE10206517A1 (de) * 2002-02-16 2003-09-04 Stoess & Co Gelatine Depotarzneimittel, Trägermaterialien für Depotarzneimittel und Verfahren zu deren Herstellung
ES2292655T3 (es) * 2002-03-15 2008-03-16 Alrise Biosystems Gmbh Microparticulas y procedimiento para su preparacion.
US9101540B2 (en) * 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US7649023B2 (en) 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery
AR039729A1 (es) * 2002-06-25 2005-03-09 Alza Corp Formulaciones de deposito de corta duracion
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
ES2605402T3 (es) * 2002-06-25 2017-03-14 Takeda Pharmaceutical Company Limited Procedimiento para producir una composición de liberación sostenida
US8252303B2 (en) * 2002-07-31 2012-08-28 Durect Corporation Injectable depot compositions and uses thereof
WO2004011054A2 (en) * 2002-07-31 2004-02-05 Alza Corporation Injectable multimodal polymer depot compositions and uses thereof
KR101476067B1 (ko) 2002-09-06 2014-12-23 인설트 테라페틱스, 인코퍼레이티드 공유결합된 치료제 전달을 위한 사이클로덱스트린-기초 중합체
BR0315304A (pt) * 2002-11-06 2005-08-16 Alza Corp Formulações com depósito para liberação controlada
EP1594517B1 (en) 2003-01-28 2007-06-20 Microbia, Inc. Compositions for the treatment of gastrointestinal disorders
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2004087213A1 (en) * 2003-04-02 2004-10-14 Ares Trading S.A. Liquid pharmaceutical formulations of fsh and lh together with a non-ionic surfactant
US20040224024A1 (en) * 2003-04-23 2004-11-11 Massachusetts Institute Of Technology Controlled drug release formulations containing polyion complexes
US20050112087A1 (en) * 2003-04-29 2005-05-26 Musso Gary F. Pharmaceutical formulations for sustained drug delivery
PT1638595E (pt) * 2003-06-20 2013-04-26 Ares Trading Sa Fsh liofilizada / formulações de hl
US8153591B2 (en) 2003-08-26 2012-04-10 Gel-Del Technologies, Inc. Protein biomaterials and biocoacervates and methods of making and using thereof
US20050049210A1 (en) * 2003-08-27 2005-03-03 Idexx Laboratories, Inc. Methods for the controlled delivery of pharmacologically active compounds
PT1682537E (pt) 2003-11-05 2012-06-20 Sarcode Bioscience Inc Moduladores de adesão celular
AU2004296851A1 (en) 2003-12-08 2005-06-23 Gel-Del Technologies, Inc. Mucoadhesive drug delivery devices and methods of making and using thereof
TW200529890A (en) * 2004-02-10 2005-09-16 Takeda Pharmaceutical Sustained-release preparations
WO2005074968A2 (en) * 2004-02-10 2005-08-18 Universiteit Maastricht Medical use of basic peptides
US7846201B2 (en) * 2004-02-20 2010-12-07 The Children's Hospital Of Philadelphia Magnetically-driven biodegradable gene delivery nanoparticles formulated with surface-attached polycationic complex
US9028829B2 (en) * 2004-02-20 2015-05-12 The Children's Hospital Of Philadelphia Uniform field magnetization and targeting of therapeutic formulations
US8562505B2 (en) * 2004-02-20 2013-10-22 The Children's Hospital Of Philadelphia Uniform field magnetization and targeting of therapeutic formulations
EP1674082A1 (de) * 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
DK1881823T3 (en) 2005-05-17 2015-03-02 Sarcode Bioscience Inc COMPOSITION AND PROCEDURES FOR TREATMENT OF EYE DISORDERS
US8882747B2 (en) * 2005-11-09 2014-11-11 The Invention Science Fund I, Llc Substance delivery system
US8945598B2 (en) * 2005-12-29 2015-02-03 Cordis Corporation Low temperature drying methods for forming drug-containing polymeric compositions
EP1837014A1 (en) * 2006-03-21 2007-09-26 Hexal Ag Subcutaneous implants containing a degradation-resistant polylactide polymer and a LH-RH analogue
ITMI20061538A1 (it) * 2006-08-02 2008-02-03 Mediolanum Pharmaceuticals Ltd Impianti sottocutanei in grado di rilasciare il principio attivo per un periodo prolungato di tempo
EP1917971A1 (en) * 2006-10-27 2008-05-07 Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) Substained release formulations comprising very low molecular weight polymers
KR100816065B1 (ko) 2006-11-27 2008-03-24 동국제약 주식회사 초기 방출억제 특성이 우수한 서방출성 마이크로캡슐의제조방법 및 이에 의해 제조되는 마이크로캡슐
JP2010516625A (ja) 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2830024T3 (es) 2007-10-19 2021-06-02 Novartis Ag Composiciones y métodos para el tratamiento del edema macular
US20090163603A1 (en) * 2007-12-20 2009-06-25 Eastman Chemical Company Sulfo-polymer powder and sulfo-polymer powder blends
US20090163449A1 (en) * 2007-12-20 2009-06-25 Eastman Chemical Company Sulfo-polymer powder and sulfo-polymer powder blends with carriers and/or additives
WO2009086483A2 (en) 2007-12-26 2009-07-09 Gel-Del Technologies, Inc. Biocompatible protein particles, particle devices and methods thereof
JOP20090061B1 (ar) * 2008-02-11 2021-08-17 Ferring Int Center Sa طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
US8080562B2 (en) 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
EP3239170B1 (en) 2008-06-04 2019-03-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010057177A2 (en) 2008-11-17 2010-05-20 Gel-Del Technologies, Inc. Protein biomaterial and biocoacervate vessel graft systems and methods of making and using thereof
US8822546B2 (en) * 2008-12-01 2014-09-02 Medtronic, Inc. Flowable pharmaceutical depot
MX366955B (es) 2009-09-15 2019-07-31 Bluelink Pharmaceuticals Inc Crlx101 para usarse en el tratamiento de cáncer.
WO2011050175A1 (en) 2009-10-21 2011-04-28 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
MX2012006441A (es) * 2009-12-22 2012-06-28 Takeda Pharmaceutical Formulacion de liberacion sostenida.
DE102010003615A1 (de) 2010-04-01 2011-10-06 Leibniz-Institut Für Polymerforschung Dresden E.V. Verfahren zur Herstellung eines Drug-Delivery-Systems auf der Basis von Polyelektrolytkomplexen
AU2011255647A1 (en) 2010-05-18 2012-11-15 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
WO2011161531A1 (en) 2010-06-24 2011-12-29 Torrent Pharmaceuticals Limited Pharmaceutical composition containing goserelin for in-situ implant
ES2513569T3 (es) * 2010-06-25 2014-10-27 Takeda Pharmaceutical Company Limited Formulación de liberación prolongada que comprende un derivado de metastina
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
AU2012250776B2 (en) 2011-05-04 2017-06-15 Balance Therapeutics, Inc. Pentylenetetrazole derivatives
KR101467275B1 (ko) * 2011-12-19 2014-12-02 주식회사 삼양바이오팜 분산성이 향상된 생분해성 고분자 미립자의 조성물 및 그 제조방법
CN110922393A (zh) 2012-07-25 2020-03-27 诺华股份有限公司 Lfa-1抑制剂及其多晶型物
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
US9545446B2 (en) 2013-02-25 2017-01-17 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
RU2715714C2 (ru) * 2013-03-04 2020-03-03 Безен Хелткэа Люксембург Сарл Сухие фармацевтические композиции, включающие наночастицы активного агента, связанные с частицами носителя
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
EP3054969B1 (en) 2013-10-10 2021-03-10 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
JP6564369B2 (ja) 2013-12-09 2019-08-21 デュレクト コーポレイション 薬学的活性剤複合体、ポリマー複合体、ならびにこれらを伴う組成物及び方法
KR20180023884A (ko) 2015-01-07 2018-03-07 트라이제미나 인코퍼레이티드 마그네슘-함유 옥시토신 제제 및 사용 방법
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744239B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
JP2019506383A (ja) 2016-01-11 2019-03-07 シナジー ファーマシューティカルズ インコーポレイテッド 潰瘍性大腸炎を治療するための製剤および方法
CN105963258B (zh) * 2016-04-26 2021-01-22 广州帝奇医药技术有限公司 一种缓释微粒的制备方法
US20210154147A1 (en) * 2018-10-19 2021-05-27 Ac Pharmaceuticals Co., Ltd. Preparation method of sustained-release microparticles
CN110954491B (zh) * 2019-12-09 2022-11-15 北京博恩特药业有限公司 用于测量醋酸戈舍瑞林缓释植入剂体外溶出度的方法
WO2021146215A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
US20230285576A1 (en) 2020-08-05 2023-09-14 Ellipses Pharma Ltd Treatment of cancer using a cyclodextrin-containing polymer-topoisomerase inhibitor conjugate and a parp inhibitor
WO2023012357A1 (en) 2021-08-05 2023-02-09 Medincell Pharmaceutical composition

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US5005602A (en) * 1985-12-24 1991-04-09 Dover Corporation Poppet valve assembly
FR2600894B1 (fr) * 1986-07-02 1989-01-13 Centre Nat Rech Scient Conjugues macromoleculaires d'hemoglobine, leur procede de preparation et leurs applications
JP2827287B2 (ja) * 1988-07-05 1998-11-25 武田薬品工業株式会社 水溶性薬物含有徐放型マイクロカプセル
US4938763B1 (en) * 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US4997643A (en) * 1989-07-12 1991-03-05 Union Carbide Chemicals And Plastics Company Inc. Polymeric salt delivery systems
US5077049A (en) * 1989-07-24 1991-12-31 Vipont Pharmaceutical, Inc. Biodegradable system for regenerating the periodontium
CH679207A5 (el) * 1989-07-28 1992-01-15 Debiopharm Sa
CA2065156A1 (en) * 1990-07-03 1992-01-04 Richard L. Dunn Intragingival delivery systems for treatment of periodontal disease
CA2046830C (en) * 1990-07-19 1999-12-14 Patrick P. Deluca Drug delivery system involving inter-action between protein or polypeptide and hydrophobic biodegradable polymer
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
US5672659A (en) * 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides

Also Published As

Publication number Publication date
JPH08501064A (ja) 1996-02-06
SE9404115D0 (sv) 1994-11-28
AU4084793A (en) 1993-12-30
DE4392401B4 (de) 2007-05-16
FR2691631B1 (fr) 1995-06-09
AT407702B (de) 2001-05-25
SE9404115L (sv) 1994-11-28
IL105710A (en) 2001-03-19
GB2282066B (en) 1996-11-06
CH688911A5 (de) 1998-05-29
NO311006B1 (no) 2001-10-01
DK176134B1 (da) 2006-09-18
MC2330A1 (fr) 1994-05-31
CA2136751A1 (en) 1993-12-09
GB2282066A (en) 1995-03-29
RU94046097A (ru) 1996-09-20
TW223018B (en) 1994-05-01
IL105710A0 (en) 1993-09-22
DK135394A (da) 1994-11-28
SK280320B6 (sk) 1999-11-08
GB9423366D0 (en) 1995-01-25
CZ293794A3 (en) 1995-03-15
NL9320034A (nl) 1995-04-03
RU2152225C1 (ru) 2000-07-10
CH690491A5 (de) 2000-09-29
NZ252268A (en) 1996-12-20
CA2136751C (en) 2006-10-31
WO1993024150A1 (en) 1993-12-09
LU88559A1 (fr) 1995-04-05
ES2107357A1 (es) 1997-11-16
NO944535L (no) 1995-01-25
SG44645A1 (en) 1997-12-19
FR2691631A1 (fr) 1993-12-03
ES2107357B1 (es) 1998-10-16
FI945553A0 (fi) 1994-11-25
NO944535D0 (no) 1994-11-25
ITMI931099A0 (it) 1993-05-27
BE1006143A3 (fr) 1994-05-24
CZ292449B6 (cs) 2003-09-17
NL195056C (nl) 2003-07-01
IE74715B1 (en) 1997-07-30
KR100293882B1 (ko) 2001-09-17
GB9211268D0 (en) 1992-07-15
IE930358A1 (en) 1993-12-01
DE4392401T1 (de) 1997-07-24
FI945553A (fi) 1995-01-25
HU9403371D0 (en) 1995-02-28
SK143494A3 (en) 1995-07-11
ITMI931099A1 (it) 1994-11-27
AU682310B2 (en) 1997-10-02
US6034175A (en) 2000-03-07
ATA901993A (de) 2000-10-15
HK133097A (en) 1997-10-24
ZA933358B (en) 1994-09-15
US20020198315A1 (en) 2002-12-26
HUT70177A (en) 1995-09-28
US5889110A (en) 1999-03-30
SE501970C2 (sv) 1995-07-03
GB9309645D0 (en) 1993-06-23
IT1271139B (it) 1997-05-27
FI112603B (fi) 2003-12-31

Similar Documents

Publication Publication Date Title
GR1001550B (el) Αλατα βασικών πεπτιδίων με πολυεστέρες που έχουν ακραία ομάδα καρβοξύ.
DE69534792D1 (de) Verabreichung von komplettem faktor viii mit hilfe eines retroviralen systems
DK1109831T3 (da) Cytotoksiske peptider modificeret ved store eller lipofile dele
CY1109699T1 (el) Νουκλεινικα οξεα που κωδικοποιουν πολυπεπτιδια πολυεπιτοπων
CY1108889T1 (el) Ανοσολογικες συνθεσεις για τη ρυθμιση της μυοστατινης σε σπονδυλωτα οντα
DK1175909T3 (da) Terapeutiske sammensætninger af antistoffer og antisense-nukleinsyrer mod Serrate
HK160995A (en) Complex compounds of bioflavonoids with phospholipids their preparation and use and pharmaceutical and cosmetic compositions containing them
CY1113218T1 (el) Υβριδιο και διμερης εκφραση πρωτεϊνων ναϊσσεριας
ATE232109T1 (de) Synthetische, vielfache tandemwiederholungen des mucinpeptides und seiner derivate und deren verwendung
ES2127831T3 (es) Unidades de expresion multicistronicas y su aplicacion.
ES2111167T3 (es) Compuestos peptidicos.
CY1112236T1 (el) Πεπτιδια που ειναι σε θεση να αναστελλουν την αλληλεπιδραση μεταξυ των πρεσενιλινων και του βητα-αμυλοειδους πεπτιδιου ή του προδρομου
ES2076999T3 (es) Peptidos anticoagulantes radiomarcados.
CY1109496T1 (el) Τρυγικο και φωσφορικο αλας της 3,4-διαμινοπυριδινης, φαρμακευτικες συνθεσεις και χρησεις αυτων
TR199700999T1 (xx) Askomisinler.
IT1212508B (it) Analoghi retro - invertiti dei penta - ed esapeptidi c - terminali della sostanza p. utili come vasodilatatori
DE69426244T2 (de) Einen für Tumore cytotoxischen Faktor enthaltende pharmazeutische Zusammensetzung
DE69032323D1 (de) Produktion und verwendung von antihelmintischen substanzen und schützenden immunogenen
PT83837B (pt) Processo para a preparacao de peptideos por utilizacao de percloratos
ATE276272T1 (de) Entzündungshemmende peptide
GR1000098B (el) Παραγωγα διοξαζοκινης, παρασκευη των και συνθεσεις που τα περιεχουν.
ATE293163T1 (de) Cyclin e spezifische konstrukte und komplexe
GR890100803A (el) Μέ?οδος παρασκευής πεπτιδικών παραγώγων.
FI942248A0 (fi) N-trityyliasparagiinihapon johdannaiset fosfonaatti-NMDA-antagonistien valmistamiseksi
CY1113674T1 (el) Τριοξειδιο του αρσενικου για χρηση στην αγωγη της λευχαιμιας

Legal Events

Date Code Title Description
ML Lapse due to non-payment of fees